Berkeley Talks: Professor David Raulet on the revolution of cancer immunology

IVRI Faculty director publishes new potential target for immunotherapy – The activation of the adaptor protein STING depends on its interactions with the phospholipid PI4P
UC Berkeley Assistant Professor in Immunology Michel DuPage published in Cancer Immunology – Separating the Good from the Bad: Tumor-Infiltrating Tregs Have Increased Fucosylation
IVRI faculty director David Raulet and collaborators, reviewed in Nature Reviews Immunology, why Natural killer (NK) cells are emerging as important new additions to the cancer therapeutic arsenal.
David Raulet’s research addresses how the immune system recognizes and responds to cancer cells and virus-infected cells. Recognized with many awards for his scientific contributions, Raulet was elected to the National Academy of Sciences in 2019 and is a Distinguished Fellow of the American Association of Immunologists.
Berkeley Students fighting Cancer – Student Technology Fund supports Drug Discovery summer Workshop at CEND –